Refine by
Pressure Reducer Articles & Analysis: Older
24 news found
Current treatment for glaucoma focuses on reducing intraocular pressure to slow down the progression of the disease and prevent visual field loss. Common drugs for lowering intraocular pressure in glaucoma include adrenergic modulators, carbonic anhydrase inhibitors, and prostaglandin analogs. ...
Thanksgiving is a time when families gather around the table to give thanks for their blessings, share a delicious meal, and create memories. It’s a holiday that encourages us to reflect on what we are grateful for and appreciate the people and opportunities in our lives. While Thanksgiving is traditionally a family-centric holiday, it’s also an excellent opportunity for businesses to ...
As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. ...
In all three trials, MINIject® met all endpoints, which included a significant reduction in both intraocular pressure (IOP) as well as hypotensive medication-use. Furthermore, no safety concerns regarding corneal endothelial health were raised across all three trials, a pivotal factor in long-term safety. ...
This innovative MIGS device, with its distinctive STAR material, provides a clear benefit to my patients to achieve the right balance of meaningful intraocular pressure reduction with favourable safety, sustained over the longer-term. ...
It also includes a built-in safety mechanism to automatically limit injection pressure helping to reduce the risks of nerve damage, promoting patient safety. ...
ByMedovate
MINIject has demonstrated meaningful and enduring intraocular pressure (IOP) reduction, combined with a favorable safety profile, in completed and ongoing trials conducted in Europe, the Americas and Asia in over 150 patients so far. ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone. The breakthrough ...
Termed the SUPRA study (Study Using Negative Pressure to Reduce Apnea), the trial will evaluate the treatment benefits and safety of applying mild external vacuum over the upper airway with the aerSleep® II device in subjects with moderate and severe OSA who are unable to use standard therapy with continuous positive airway pressure (CPAP) ...
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. ...
— April 29, 2021 — Sommetrics is pleased to announce US Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application to conduct a pivotal in-home clinical trial of its aerSleep II system. The Study Using negative Pressure to Reduce Apnea (SUPRA) clinical trial will evaluate the safety and effectiveness of the ...
That includes managing their brain health to reduce certain risk factors, potentially delaying or even reversing memory loss. ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever release of five-year follow-up data from its HORIZON pivotal trial. ...
Used for only 20 minutes per day for a period of six weeks and then twice per week, the therapy is clinically proven to improve the quality of sleep by significantly reducing obstructive sleep apnea and snoring. Signifier Medical Technologies, an innovator in the sleep disordered breathing market, today announced that eXciteOSA®, the first and only daytime intraoral ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure in patients with open-angle glaucoma, is proud to be the recipient of multiple awards and recognition this year for its innovation and excellence in helping to change the standard of care for the world’s 80 million glaucoma ...
The latest findings from the HORIZON study confirm the benefits of the Hydrus Microstent reported at three years in Ophthalmology and show that those benefits are maintained through four years, notably reducing the need for invasive secondary glaucoma surgery and medications to control glaucoma. ...
TWO2 therapy has been shown to be particularly helpful in treating edematous wounds, by providing cyclical-pressure oxygen to help reduce edema via noncontact compression. TWO2 treatments are applied at home without the need to remove gas permeable dressings, with oxygen diffusing easily through CCD, UNNA boots and TCC adjunctive treatments. TWO2 has been further ...
Key findings at 3 years include: In patients undergoing combined cataract surgery and Hydrus placement, mean IOP dropped over 20% with concurrent elimination of a full medication In patients undergoing standalone Hydrus placement, mean IOP dropped roughly 30%, with concurrent elimination of a full medication (this group had higher baseline pressures due to more severe ...
In a cohort of nearly 250 eyes followed for three years, intraocular pressure was reduced by 29% with a commensurate reduction of one medication compared to preoperative levels. ...